spironolactone and Body Weight studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

Excerpt	Relevance	Reference
"A total of 148 patients with cirrhosis, ascites and serum sodium >130 mmol/L were included in a multicentre, double-blind, randomized, controlled study of 14 days comparing three fixed doses of satavaptan (5 mg, 12."	9.14	Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. ( Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP, 2010)
"Torsemide increased sodium excretion substantially in patients with cirrhosis and ascites who were receiving spironolactone."	9.07	A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis. ( Applefeld, JJ; Dukes, GE; Hak, LJ; Kasmer, RJ; McClain, CJ; Wermeling, DP, 1994)
"The effect of adding spironolactone (Aldactone) on muscle electrolytes was studied in 48 patients with arterial hypertension and/or congestive heart failure who had received conventional diuretic treatment, including a potassium supplement, for more than 1 year."	9.06	Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. ( Dyckner, T; Wester, PO; Widman, L, 1986)
"The present study was undertaken to determine whether or not spironolactone could induce drug-metabolizing enzymes in patients with ascites due to alcoholic cirrhosis of the liver."	9.05	Spironolactone and enzyme induction in patients with alcoholic cirrhosis. ( Dhumeaux, D; Joanne, C; Miguet, JP; Thebault-Lucas, A; Vuitton, D, 1980)
"Eighteen patients with hepatic cirrhosis or nephrotic syndrome and having edema and/or ascites were treated during successive periods with metolazone 5 to 40 mg/day, spironolactone 100 mg/day, and with both diuretics concurrently."	9.04	Metolazone and spironolactone in cirrhosis and the nephrotic syndrome. ( Arruda, JA; Dhupelia, VB; Kane, RE; Lang, GR; Nascimento, L; Westenfelder, C, 1977)
"Adult Wistar rats were randomly distributed into 4 groups; controls, spironolactone treated rats (Spir, 50mg/kg/day), hyperthyroid rats (Hyper, daily intraperitoneal levothyroxine 0."	7.96	The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats. ( Aljohmani, AI; Alzoubi, KH; Mayyas, FA, 2020)
"Recent evidence suggests that treatment with mineralocorticoid receptor antagonist suppressed local inflammation in vascular tissues or cardiomyocytes; therefore, we examined the effect of spironolactone on glucose and lipid metabolism in a mouse model with diet-induced diabetes and nonalcoholic fatty liver disease."	7.76	Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. ( Kenmochi, H; Koya, D; Miyashita, Y; Ojima, M; Sasahara, M; Sasaki, M; Sasaoka, T; Tsuneki, H; Wada, T, 2010)
" To elucidate its significance for myocardial fibrosis in the hypertensive heart, we used a mouse model with infusion of angiotensin II and examined results by histology, immunohistochemistry, in situ hybridization, and quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)."	7.74	Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. ( Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T, 2007)
"To examine the effects of eplerenone, a selective aldosterone blocker, on cardiac function after myocardial infarction (MI) and myocardial remodelling related transcriptional factors and mRNA expression in non-infarcted myocardium."	7.73	Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. ( Akioka, K; Enomoto, S; Iwao, H; Izumi, Y; Kim, S; Kusuyama, T; Matsumoto, R; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2005)
"We have demonstrated previously that infusion of angiotensin II (AngII) into hyperlipidemic mice augments atherosclerosis and results in the formation of abdominal aortic aneurysms (AAA)."	7.73	Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. ( Cassis, LA; Daugherty, A; Helton, MJ; Howatt, DA; King, VL, 2005)
"A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%)."	7.72	Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. ( Aaronson, KD; Koelling, TM; Tamirisa, KP, 2004)
"The effects of the mineralocorticoid antagonist mespirenone on the development and maintenance of aldosterone-induced hypertension in Sprague-Dawley rats has been studied."	7.68	Effect of a new mineralocorticoid antagonist mespirenone on aldosterone-induced hypertension. ( Agarwal, M; Kalimi, M; Opoku, J; Qureshi, D, 1991)
"We have studied the efficacy of urea in the treatment of hyponatremia and hydrosaline retention in cirrhotic patients with ascites resistant to diuretics."	7.67	Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. ( Cauchie, P; Decaux, G; Delwiche, F; Flamion, B; Mols, P, 1986)
"The effect of spironolactone on the urinary excretion of prostaglandins was studied in patients with liver cirrhosis and ascites."	7.67	Effect of spironolactone on renal prostaglandin excretion in patients with liver cirrhosis and ascites. ( Guarner, F; Medina, JF; Milazzo, A; Prieto, J; Quiroga, J, 1986)
"Serum estradiol (E2) levels and resolution of endometriosis were evaluated in 42 women after 75 days of danazol treatment."	7.67	Serum estradiol and danazol. I. Endometriosis response, side effects, administration interval, concurrent spironolactone and dexamethasone. ( Curole, DN; Dickey, RP; Taylor, SN, 1984)
"In order to evaluate the relationship between aldosterone status and the blood pressure-lowering effect of spironolactone, 38 patients with essential hypertension were treated with spironolactone (400 mg/day) during one week in hospital on a rigidly sodium-restricted diet."	7.66	Role of aldosterone in the antihypertensive effect of spironolactone in essential hypertension. ( Benraad, H; Benraad, T; Drayer, J; Hoefnagels, W; Kloppenborg, P, 1978)
"Intrarenal handling of uric acid was studied in 12 patients with essential hypertension under spironolactone treatment (200 mg/day)."	7.66	Changes in intrarenal uric acid handling during chronic spironolactone treatment in patients with essential hypertension. ( Boer, P; Dorhout Mees, EJ; Peuker, KH; Roos, JC, 1982)
"Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day)."	7.66	Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. ( Blum, I; Bruhis, S; Kaufman, H, 1981)
"The anti-hypertensive effect of spironolactone and thiabutazide was tested on 47 unselected patients with primary hypertension."	7.65	[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]. ( Braun, B; Klaus, D; Klump, F; Lemke, R; Zehner, J; Zöfel, P, 1975)
"During treatment with indomethacin in a patient with Bartter's syndrome, hypokalemia, high plasma renin concentration, hyperaldosteronism and decreased sensitivity to angiotensin infusion were corrected."	7.65	Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. ( Amery, A; Clement, J; Michielsen, P; van Damme B, B; Verberckmoes, R, 1976)
"The effect of prolonged preoperative treatment with spironolactone has been studied in a series of 67 patients with hypertension, aldosterone excess, and low plasma renin."	7.65	Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. ( Brown, JJ; Davies, DL; Ferriss, JB; Fraser, R; Haywood, E; Lever, AF; Robertson, JI, 1972)
"Patients with Gitelman syndrome (GS), an inherited salt-losing tubulopathy, are usually treated with potassium-sparing diuretics or nonsteroidal anti-inflammatory drugs and oral potassium and magnesium supplementations."	6.80	Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. ( Allard, J; Azizi, M; Baron, S; Bergerot, D; Blanchard, A; Bridoux, F; Caumont-Prim, A; Desport, E; Dubourg, L; Essig, M; Monge, M; Tack, I; Vallet, M; Vargas-Poussou, R, 2015)
" To develop an effective but safe regimen for treatment of cirrhotic ascites, a two-part crossover study was done."	6.64	An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide. ( Fuller, RK; Gobezie, GC; Khambatta, PB, 1977)
"Treatment with spironolactone resulted in more marked hyperreninism (47."	6.64	Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension. ( Benraad, TJ; Drayer, JI; Festen, J; Kloppenborg, PW; van't Laar, A, 1975)
"Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV."	5.46	Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. ( Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M, 2017)
"Liver cirrhosis was induced in Sprague-Dawley rats by common bile duct ligation (BDL), and sham-operated rats were the controls."	5.42	The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats. ( Chang, CC; Ho, HL; Hsin, IF; Hsu, SJ; Huang, HC; Huo, TI; Lee, FY; Lee, SD; Lin, HC; Wang, SS, 2015)
"Thus, in rats with aldosteronism, in which a reduction in effective refractory period was not evident, the mechanism for VA susceptibility is presumably linked to a decrease in conduction velocity and/or increased dispersion of refractoriness, probably caused by consequential myocardial fibrosis."	5.37	Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism. ( Bellary, SR; de Jongh Curry, AL; Deshmukh, PA; Kamalov, G; Magotra, M; Schwender, FT; Sun, Y; Weber, KT, 2011)
"Aldosterone promotes renal fibrosis via the mineralocorticoid receptor (MR), thus contributing to hypertension-induced nephropathy."	5.35	Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. ( Camp, JR; Cavallari, LH; Fashingbauer, LA; Geenen, DL; King, ST, 2008)
"High salt diet causes cardiac hypertrophy and fibrosis and increases cardiac aldosterone, while decreasing plasma aldosterone."	5.32	Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. ( Lal, A; Leenen, FH; Veinot, JP, 2003)
"Aldosterone is a risk factor for stroke, and the literature suggests it may play a role in increasing the expression of the receptor for EGF (EGFR)."	5.31	Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. ( Dorrance, AM; Grekin, R; Osborn, HL; Webb, RC, 2001)
" The data shows that this dosage of spironolactone gave minor adjustments of the systemic and renal circulation in spite of the consistent changes in BW, PV, PRA and PA."	5.26	Haemodynamic effects of treatment and withdrawal of spironolactone in essential hypertension. ( Falch, DK; Johansson, R; Norman, N; Odegaard, AE, 1979)
"The combination of tolvaptan with conventional diuretics increases urine output without renal dysfunction and can be effective for postoperative fluid management and appropriate body weight reduction."	5.22	Effects of short-term administration of tolvaptan after open heart surgery. ( Iwahasi, T; Iwahori, A; Iwasaki, T; Koizumi, N; Maruno, K; Matsuyama, K; Nishibe, T; Ogino, H; Takahashi, S; Toguchi, K, 2016)
"We conclude that 6 weeks of treatment with spironolactone does not change insulin sensitivity or endothelial function in normotensive obese individuals with no other comorbidities."	5.19	Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. ( Adler, GK; Garg, R; Kneen, L; Williams, GH, 2014)
"A total of 148 patients with cirrhosis, ascites and serum sodium >130 mmol/L were included in a multicentre, double-blind, randomized, controlled study of 14 days comparing three fixed doses of satavaptan (5 mg, 12."	5.14	Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. ( Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP, 2010)
"This study explored the effect of the anti-androgen spironolactone on sex-hormone binding globulin (SHBG) and the distribution of circulating testosterone (T) into various free and bound fractions in seven women with hirsutism assessed before and then monthly for three months on a regimen of spironolactone, 100 mg bid as the sole therapeutic agent."	5.08	The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women. ( Kirschner, MA; Lerário, AC; Luthold, WW; Marcondes, JA; Mendonça, BB; Minanni, SL; Nery, M; Wajchenberg, BL, 1995)
"Torsemide increased sodium excretion substantially in patients with cirrhosis and ascites who were receiving spironolactone."	5.07	A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis. ( Applefeld, JJ; Dukes, GE; Hak, LJ; Kasmer, RJ; McClain, CJ; Wermeling, DP, 1994)
"The effect of adding spironolactone (Aldactone) on muscle electrolytes was studied in 48 patients with arterial hypertension and/or congestive heart failure who had received conventional diuretic treatment, including a potassium supplement, for more than 1 year."	5.06	Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. ( Dyckner, T; Wester, PO; Widman, L, 1986)
"The present study was undertaken to determine whether or not spironolactone could induce drug-metabolizing enzymes in patients with ascites due to alcoholic cirrhosis of the liver."	5.05	Spironolactone and enzyme induction in patients with alcoholic cirrhosis. ( Dhumeaux, D; Joanne, C; Miguet, JP; Thebault-Lucas, A; Vuitton, D, 1980)
"To compare the efficacy of three commonly used diuretic regimens in the treatment of ascites, we randomized 90 patients to three treatment groups: Sequential Spironolactone (spironolactone followed by furosemide if necessary), Combination (spironolactone and furosemide in combination), and Furosemide (furosemide given alone)."	5.05	Diuresis in the ascitic patient: a randomized controlled trial of three regimens. ( Fogel, MR; Gregory, PB; Knauer, CM; Miller, RG; Neal, EA; Sawhney, VK, 1981)
"Eighteen patients with hepatic cirrhosis or nephrotic syndrome and having edema and/or ascites were treated during successive periods with metolazone 5 to 40 mg/day, spironolactone 100 mg/day, and with both diuretics concurrently."	5.04	Metolazone and spironolactone in cirrhosis and the nephrotic syndrome. ( Arruda, JA; Dhupelia, VB; Kane, RE; Lang, GR; Nascimento, L; Westenfelder, C, 1977)
"This study was designed to compare the effectiveness of spironolactone, hydrochlorothiazide, and combined spironolactone-hydrochlorothiazide therapy in patients with low renin and those with normal renin essential hypertension."	5.04	Diuretic therapies in low renin and normal renin essential hypertension. ( Brooks, CS; Johnson, CA; Kotchen, JM; Kotchen, TA, 1977)
"Adult Wistar rats were randomly distributed into 4 groups; controls, spironolactone treated rats (Spir, 50mg/kg/day), hyperthyroid rats (Hyper, daily intraperitoneal levothyroxine 0."	3.96	The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats. ( Aljohmani, AI; Alzoubi, KH; Mayyas, FA, 2020)
" We evaluated the efficacy of MR antagonism by spironolactone in two experimental PH models; mouse chronic hypoxia-induced PH (prevention model) and rat monocrotaline-induced PH (prevention and treatment models)."	3.79	Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. ( Fanburg, BL; Hill, NS; Jaffe, IZ; Preston, IR; Sagliani, KD; Warburton, RR, 2013)
"Recent evidence suggests that treatment with mineralocorticoid receptor antagonist suppressed local inflammation in vascular tissues or cardiomyocytes; therefore, we examined the effect of spironolactone on glucose and lipid metabolism in a mouse model with diet-induced diabetes and nonalcoholic fatty liver disease."	3.76	Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. ( Kenmochi, H; Koya, D; Miyashita, Y; Ojima, M; Sasahara, M; Sasaki, M; Sasaoka, T; Tsuneki, H; Wada, T, 2010)
" We investigated the effects of spironolactone, an unselective mineralocorticoid-receptor antagonist, on in vivo cardiac haemodynamics, cardiomyocyte damage and fibrosis in prednisolone treated Sgcd-null mice."	3.76	Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Lochmüller, H; MacGowan, GA; Straub, V, 2010)
" To elucidate its significance for myocardial fibrosis in the hypertensive heart, we used a mouse model with infusion of angiotensin II and examined results by histology, immunohistochemistry, in situ hybridization, and quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)."	3.74	Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. ( Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T, 2007)
"The spironolactone Y5 antagonist significantly reduced body weight in C57BL DIO mice, but not in Npy5r(-/-) DIO mice."	3.74	Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. ( Fukami, T; Gomori, A; Ishihara, A; Ito, J; Iwaasa, H; Kanatani, A; Kitazawa, H; MacNeil, DJ; Mashiko, S; Matsushita, H; Mitobe, Y; Moriya, R; Takahashi, T; Van der Ploeg, LH, 2008)
"We have demonstrated previously that infusion of angiotensin II (AngII) into hyperlipidemic mice augments atherosclerosis and results in the formation of abdominal aortic aneurysms (AAA)."	3.73	Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. ( Cassis, LA; Daugherty, A; Helton, MJ; Howatt, DA; King, VL, 2005)
"To examine the effects of eplerenone, a selective aldosterone blocker, on cardiac function after myocardial infarction (MI) and myocardial remodelling related transcriptional factors and mRNA expression in non-infarcted myocardium."	3.73	Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. ( Akioka, K; Enomoto, S; Iwao, H; Izumi, Y; Kim, S; Kusuyama, T; Matsumoto, R; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2005)
"The purpose of this study was to investigate the role of the renin-angiotensin-aldosterone system in hypertension development and cardiovascular structural changes in a salt-sensitive hypertensive model induced by capsaicin (CAP)."	3.72	Control of vascular changes by renin-angiotensin-aldosterone system in salt-sensitive hypertension. ( Gao, YJ; He, CC; Lee, RM; Li, N; Luo, BH; Su, CJ; Yi, JJ; Zeng, ZH, 2004)
"A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%)."	3.72	Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. ( Aaronson, KD; Koelling, TM; Tamirisa, KP, 2004)
" The present study investigated the effects of the aldosterone receptor antagonists spironolactone and eplerenone on endothelial function in liquorice-induced hypertension."	3.71	Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. ( Lüscher, TF; Quaschning, T; Ruschitzka, F; Shaw, S, 2001)
"Of those physiological factors which have been examined in this study, age and total body weight were most closely correlated with digoxin clearance."	3.70	Population analysis for the optimization of digoxin treatment in Japanese paediatric patients. ( Higuchi, S; Minemoto, M; Suematsu, F; Yukawa, E, 1999)
"5 mL/kg of body weight (BW), PO], sucrose (2 g/kg in a 20% aqueous solution, p."	3.70	A reliable, practical, and economical protocol for inducing diarrhea and severe dehydration in the neonatal calf. ( Constable, PD; Drackley, JK; Foreman, JH; Morin, DE; Thurmon, JC; Walker, PG, 1998)
"The effect of dextroamphetamine sulfate (Dexedrine) on plasma opioid peptides, hormones, and other metabolites was studied in eight female subjects with idiopathic (orthostatic) edema and five healthy females."	3.69	Opioid peptides, adrenocorticotrophic hormone, and idiopathic (orthostatic) edema. ( Bhathena, SJ; Canary, JJ; Gannon, CA; Glen, ML; Kennedy, BW; Smith, PM; Werman, MJ, 1994)
"The effects of the mineralocorticoid antagonist mespirenone on the development and maintenance of aldosterone-induced hypertension in Sprague-Dawley rats has been studied."	3.68	Effect of a new mineralocorticoid antagonist mespirenone on aldosterone-induced hypertension. ( Agarwal, M; Kalimi, M; Opoku, J; Qureshi, D, 1991)
"Serum estradiol (E2) levels and resolution of endometriosis were evaluated in 42 women after 75 days of danazol treatment."	3.67	Serum estradiol and danazol. I. Endometriosis response, side effects, administration interval, concurrent spironolactone and dexamethasone. ( Curole, DN; Dickey, RP; Taylor, SN, 1984)
"The effect of spironolactone on the urinary excretion of prostaglandins was studied in patients with liver cirrhosis and ascites."	3.67	Effect of spironolactone on renal prostaglandin excretion in patients with liver cirrhosis and ascites. ( Guarner, F; Medina, JF; Milazzo, A; Prieto, J; Quiroga, J, 1986)
"We have studied the efficacy of urea in the treatment of hyponatremia and hydrosaline retention in cirrhotic patients with ascites resistant to diuretics."	3.67	Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. ( Cauchie, P; Decaux, G; Delwiche, F; Flamion, B; Mols, P, 1986)
"Intrarenal handling of uric acid was studied in 12 patients with essential hypertension under spironolactone treatment (200 mg/day)."	3.66	Changes in intrarenal uric acid handling during chronic spironolactone treatment in patients with essential hypertension. ( Boer, P; Dorhout Mees, EJ; Peuker, KH; Roos, JC, 1982)
"In patients with hypertension resistant to three or four drugs including a thiazide diuretic substitution of frusemide for the thiazide, or the addition of spironolactone, produced significant reductions in blood pressure and body weight."	3.66	Diuretic treatment of resistant hypertension. ( Freestone, S; Ramsay, LE; Silas, JH, 1980)
"Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day)."	3.66	Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. ( Blum, I; Bruhis, S; Kaufman, H, 1981)
"In order to evaluate the relationship between aldosterone status and the blood pressure-lowering effect of spironolactone, 38 patients with essential hypertension were treated with spironolactone (400 mg/day) during one week in hospital on a rigidly sodium-restricted diet."	3.66	Role of aldosterone in the antihypertensive effect of spironolactone in essential hypertension. ( Benraad, H; Benraad, T; Drayer, J; Hoefnagels, W; Kloppenborg, P, 1978)
" One became oedema-free with frusemide 240 mg daily, three became oedema-free with frusemide 500 mg daily, and two required a combination of high-dose frusemide and spironolactone."	3.65	Salt-poor human albumin in management of nephrotic syndrome. ( Cash, JD; Davison, AM; Lambie, AT; Verth, AH, 1974)
"During treatment with indomethacin in a patient with Bartter's syndrome, hypokalemia, high plasma renin concentration, hyperaldosteronism and decreased sensitivity to angiotensin infusion were corrected."	3.65	Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. ( Amery, A; Clement, J; Michielsen, P; van Damme B, B; Verberckmoes, R, 1976)
"The effects of pretreatment for 4 days with the hepatic microsomal enzyme inducers phenobarbital (8 mg/100 g body weight), spironolactone (20 mg/100 g body weight) and pregnenolone-16alpha-carbonitrile (7 mg/100 g body weight) on bile flow and bile pipid secretion have been compared in rats."	3.65	Effect of phenobarbital, spironolactone and pregnenolone-16 alpha-carbonitrile on bile formation in the rat. ( Paumgartner, G; Schwarz, HP; von Bergmann, K, 1975)
"The anti-hypertensive effect of spironolactone and thiabutazide was tested on 47 unselected patients with primary hypertension."	3.65	[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]. ( Braun, B; Klaus, D; Klump, F; Lemke, R; Zehner, J; Zöfel, P, 1975)
"The effect of prolonged preoperative treatment with spironolactone has been studied in a series of 67 patients with hypertension, aldosterone excess, and low plasma renin."	3.65	Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. ( Brown, JJ; Davies, DL; Ferriss, JB; Fraser, R; Haywood, E; Lever, AF; Robertson, JI, 1972)
"Patients with Gitelman syndrome (GS), an inherited salt-losing tubulopathy, are usually treated with potassium-sparing diuretics or nonsteroidal anti-inflammatory drugs and oral potassium and magnesium supplementations."	2.80	Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. ( Allard, J; Azizi, M; Baron, S; Bergerot, D; Blanchard, A; Bridoux, F; Caumont-Prim, A; Desport, E; Dubourg, L; Essig, M; Monge, M; Tack, I; Vallet, M; Vargas-Poussou, R, 2015)
" 2 Spironolactone and triamterene had significant and parallel dose-response curves for plasma potassium, with a relative potency for triamterene:spironolactone of 0."	2.65	Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypokalaemia. ( Jackson, PR; Ramsay, LE; Wakefield, V, 1982)
"Treatment with spironolactone resulted in more marked hyperreninism (47."	2.64	Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension. ( Benraad, TJ; Drayer, JI; Festen, J; Kloppenborg, PW; van't Laar, A, 1975)
" To develop an effective but safe regimen for treatment of cirrhotic ascites, a two-part crossover study was done."	2.64	An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide. ( Fuller, RK; Gobezie, GC; Khambatta, PB, 1977)
"Aldosterone was given for the last 4 months."	1.72	Effect of Metabolic Adaptation by Voluntary Running Wheel Activity and Aldosterone Inhibition on Renal Function in Female Spontaneously Hypertensive Rats. ( Atmanspacher, F; Grgic, I; Schlüter, KD; Schreckenberg, R; Wolf, A, 2022)
" We determined the effects of SR alone or in combination with the antioxidant α-glycosyl isoquercitrin (AGIQ) on hyperlipidemia- and steatosis-related precancerous lesions in high-fat diet (HFD)-fed rats subjected to a two-stage hepatocarcinogenesis model."	1.48	Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation. ( Eguchi, A; Hayashi, SM; Kawashima, M; Kimura, M; Koyanagi, M; Makino, E; Maronpot, RR; Mizukami, S; Murayama, H; Nagahara, R; Nakamura, M; Ohtsuka, R; Shibutani, M; Takahashi, N; Yoshida, T, 2018)
"Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV."	1.46	Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. ( Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M, 2017)
"Plasma aldosterone is elevated in type 2 diabetes and obesity in experimental and clinical studies and can act to inhibit both glucose-stimulated insulin secretion by the β-cell and insulin signaling."	1.43	Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats. ( Bornstein, SR; Brown, NF; Brunssen, C; Deussen, A; Eisenhofer, G; Engelmann, F; Hofmann, A; Huber, J; Jannasch, A; Martin, M; Mittag, J; Morawietz, H; Peitzsch, M; Streicher, R; Weldon, SM, 2016)
"Spironolactone treatment did not affect blood pressure, fasting glucose levels or weight gain, but increased serum potassium and total cholesterol in both, diabetic and control mice."	1.42	Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus. ( Bruder-Nascimento, T; Cau, SB; Lopes, RA; Manzato, CP; Mestriner, FL; Montezano, AC; Neves, KB; Nguyen Dinh Cat, A; Silva, MA; Tostes, RC; Touyz, RM, 2015)
"Liver cirrhosis was induced in Sprague-Dawley rats by common bile duct ligation (BDL), and sham-operated rats were the controls."	1.42	The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats. ( Chang, CC; Ho, HL; Hsin, IF; Hsu, SJ; Huang, HC; Huo, TI; Lee, FY; Lee, SD; Lin, HC; Wang, SS, 2015)
"Spironolactone treatment also improved cognitive function in ovariectomized-KKAy mice, but failed to improve it in those with administration of estradiol (200 µg/kg per day)."	1.38	Improvement of cognitive impairment in female type 2 diabetes mellitus mice by spironolactone. ( Horiuchi, M; Ito, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K, 2012)
"Thus, in rats with aldosteronism, in which a reduction in effective refractory period was not evident, the mechanism for VA susceptibility is presumably linked to a decrease in conduction velocity and/or increased dispersion of refractoriness, probably caused by consequential myocardial fibrosis."	1.37	Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism. ( Bellary, SR; de Jongh Curry, AL; Deshmukh, PA; Kamalov, G; Magotra, M; Schwender, FT; Sun, Y; Weber, KT, 2011)
"Aldosterone and high salt were associated with lower NO levels and greater renal oxidative stress."	1.37	Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4. ( Adiyiah, J; Bayorh, MA; Eatman, D; Lyn, D; Rollins-Hairston, A, 2011)
"Spironolactone treatment did not alter SBP."	1.36	The glucocorticoid receptor is required for experimental adrenocorticotrophic hormone-induced hypertension in mice. ( Cole, TJ; McKenzie, KU; Schyvens, CG; Vickers, JJ; Whitworth, JA; Zhang, Y, 2010)
"In aldosterone-treated and aldosterone + spironolactone-treated rats, aldosterone plasma levels were increased by fourfold."	1.35	Genomic regulation of intestinal amino acid transporters by aldosterone. ( Amaral, JS; Pinho, MJ; Soares-da-Silva, P, 2008)
"Aldosterone promotes renal fibrosis via the mineralocorticoid receptor (MR), thus contributing to hypertension-induced nephropathy."	1.35	Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. ( Camp, JR; Cavallari, LH; Fashingbauer, LA; Geenen, DL; King, ST, 2008)
"The spironolactone treatment did not block normal glucocorticoid receptor-mediated immune-suppression functions because mice receiving prednisolone, either with or without spironolactone, maintained normal body weights, hematocrits, and serum immune complexes."	1.33	Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. ( Gross, ND; Kempton, JB; Trune, DR, 2006)
"Although primary aldosteronism is a rare occurrence in children, the condition appears to deserve special attention not only from the viewpoint of growth failure and hypokalaemia but from the occurrence of late organ damage to the kidney and heart."	1.33	Long-term follow-up of a girl with primary aldosteronism: effect of potassium supplement. ( Higashino, H; Hirose, Y; Isozaki, Y; Kobayashi, Y; Noda, Y; Takaya, J, 2005)
"High salt diet causes cardiac hypertrophy and fibrosis and increases cardiac aldosterone, while decreasing plasma aldosterone."	1.32	Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. ( Lal, A; Leenen, FH; Veinot, JP, 2003)
"Aldosterone is a risk factor for stroke, and the literature suggests it may play a role in increasing the expression of the receptor for EGF (EGFR)."	1.31	Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. ( Dorrance, AM; Grekin, R; Osborn, HL; Webb, RC, 2001)
"Spironolactone did not enhance water and electrolyte excretion."	1.30	Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. ( Chander, PN; Khanna, K; Rocha, R; Stier, CT; Zuckerman, A, 1998)
" Chronic administration of spironolactone prevented the development of hypertension but failed to prevent other adaptive physiological changes characteristically occurring during exposure to cold and seen in the cold-treated control rats."	1.28	Effect of chronic treatment with clonidine and spironolactone on cold-induced elevation of blood pressure. ( Baron, A; Fregly, MJ; Riesselmann, A, 1991)
"The diagnosis of Bartter's syndrome was made in a 9-month-old boy investigated for poor weight and height gain."	1.26	Treatment of Bartter's syndrome in early childhood with prostaglandin synthetase inhibitors. ( Lee, MR; Littlewood, JM; Meadow, SR, 1978)
"Hyperaldosteronism is an important factor contributing to fluid and sodium retention in infants with heart failure."	1.26	The occurrence of hyperaldosteronism in infants with congestive heart failure. ( Baylen, BG; Johnson, G; Kaplan, S; Srivastava, L; Tsang, R, 1980)
"4."	1.26	The effect of mineralocorticoid administration on urine free dopamine in man. ( Lee, MR; Oates, NS; Perkins, CM, 1980)
" The data shows that this dosage of spironolactone gave minor adjustments of the systemic and renal circulation in spite of the consistent changes in BW, PV, PRA and PA."	1.26	Haemodynamic effects of treatment and withdrawal of spironolactone in essential hypertension. ( Falch, DK; Johansson, R; Norman, N; Odegaard, AE, 1979)

Research

Studies (199)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

Timeframe	Studies, this research(%)	All Research%
pre-1990	125 (62.81)	18.7374
1990's	18 (9.05)	18.2507
2000's	33 (16.58)	29.6817
2010's	21 (10.55)	24.3611
2020's	2 (1.01)	2.80

Authors	Studies
Atmanspacher, F	1
Schreckenberg, R	1
Wolf, A	1
Grgic, I	1
Schlüter, KD	1
Mayyas, FA	1
Aljohmani, AI	1
Alzoubi, KH	1
Olatunji, LA	1
Usman, TO	1
Akinade, AI	1
Adeyanju, OA	1
Kim, I	1
Soladoye, AO	1
Miyazaki, M	1
Yada, M	1
Tanaka, K	1
Senjyu, T	1
Goya, T	1
Motomura, K	1
Kohjima, M	1
Kato, M	1
Masumoto, A	1
Kotoh, K	1
Murayama, H	1
Eguchi, A	1
Nakamura, M	1
Kawashima, M	1
Nagahara, R	1
Mizukami, S	1
Kimura, M	1
Makino, E	1
Takahashi, N	1
Ohtsuka, R	1
Koyanagi, M	1
Hayashi, SM	1
Maronpot, RR	1
Shibutani, M	1
Yoshida, T	2
Grodin, JL	1
Philips, S	1
Mullens, W	1
Nijst, P	1
Martens, P	1
Fang, JC	1
Drazner, MH	1
Tang, WHW	1
Pandey, A	1
Preston, IR	1
Sagliani, KD	1
Warburton, RR	1
Hill, NS	1
Fanburg, BL	1
Jaffe, IZ	1
Springer, J	1
Tschirner, A	1
Haghikia, A	1
von Haehling, S	1
Lal, H	1
Grzesiak, A	1
Kaschina, E	1
Palus, S	1
Pötsch, M	1
von Websky, K	1
Hocher, B	1
Latouche, C	1
Jaisser, F	1
Morawietz, L	1
Coats, AJ	1
Beadle, J	1
Argiles, JM	1
Thum, T	1
Földes, G	1
Doehner, W	1
Hilfiker-Kleiner, D	1
Force, T	1
Anker, SD	1
Garg, R	1
Kneen, L	1
Williams, GH	1
Adler, GK	1
Blanchard, A	1
Vargas-Poussou, R	1
Vallet, M	1
Caumont-Prim, A	1
Allard, J	1
Desport, E	1
Dubourg, L	1
Monge, M	1
Bergerot, D	1
Baron, S	1
Essig, M	1
Bridoux, F	1
Tack, I	1
Azizi, M	1
Silva, MA	1
Cau, SB	1
Lopes, RA	1
Manzato, CP	1
Neves, KB	1
Bruder-Nascimento, T	1
Mestriner, FL	1
Montezano, AC	1
Nguyen Dinh Cat, A	1
Touyz, RM	1
Tostes, RC	1
Ferreira, JP	1
Santos, M	1
Oliveira, JC	1
Marques, I	1
Bettencourt, P	1
Carvalho, H	1
Hsu, SJ	1
Wang, SS	1
Huo, TI	1
Lee, FY	1
Huang, HC	1
Chang, CC	1
Hsin, IF	1
Ho, HL	1
Lin, HC	1
Lee, SD	1
Matsuyama, K	1
Koizumi, N	1
Nishibe, T	1
Iwasaki, T	1
Iwahasi, T	1
Toguchi, K	1
Takahashi, S	1
Iwahori, A	1
Maruno, K	1
Ogino, H	1
Hofmann, A	1
Brunssen, C	1
Peitzsch, M	1
Martin, M	1
Mittag, J	1
Jannasch, A	1
Engelmann, F	1
Brown, NF	1
Weldon, SM	1
Huber, J	1
Streicher, R	1
Deussen, A	1
Eisenhofer, G	1
Bornstein, SR	1
Morawietz, H	1
Khachab, M	1
Kanaan, A	1
Awad, D	1
Deeba, E	1
Osman, S	1
Nassar, CF	1
Cavallari, LH	1
Fashingbauer, LA	1
Camp, JR	1
King, ST	1
Geenen, DL	1
Waanders, F	1
Rienstra, H	1
Boer, MW	1
Zandvoort, A	1
Rozing, J	1
Navis, G	1
van Goor, H	1
Hillebrands, JL	1
Goyal, BR	1
Solanki, N	1
Goyal, RK	1
Mehta, AA	1
Mori, T	1
Kurumazuka, D	1
Matsumoto, C	1
Shirakawa, H	1
Kimura, S	1
Kitada, K	1
Kobayashi, K	1
Matsuda, H	1
Hayashi, T	1
Kitaura, Y	1
Matsumura, Y	1
Bauer, R	1
Blain, A	1
Greally, E	1
Lochmüller, H	1
Bushby, K	1
MacGowan, GA	1
Straub, V	1
Ginès, P	1
Wong, F	1
Watson, H	1
Terg, R	1
Bruha, R	1
Zarski, JP	1
Dudley, F	1
Wada, T	1
Kenmochi, H	1
Miyashita, Y	1
Sasaki, M	1
Ojima, M	1
Sasahara, M	1
Koya, D	1
Tsuneki, H	1
Sasaoka, T	1
Zhang, Y	1
Schyvens, CG	1
Cole, TJ	1
McKenzie, KU	1
Vickers, JJ	1
Whitworth, JA	1
Bayorh, MA	1
Rollins-Hairston, A	1
Adiyiah, J	1
Lyn, D	1
Eatman, D	1
Sakata, A	1
Mogi, M	1
Iwanami, J	1
Tsukuda, K	1
Min, LJ	1
Jing, F	1
Ohshima, K	1
Ito, M	1
Horiuchi, M	1
Deshmukh, PA	1
Bellary, SR	1
Schwender, FT	1
Kamalov, G	1
Magotra, M	1
de Jongh Curry, AL	1
Sun, Y	1
Weber, KT	1
Rocha, R	2
Martin-Berger, CL	1
Yang, P	1
Scherrer, R	1
Delyani, J	1
McMahon, E	1
Goineau, S	1
Pape, D	1
Guillo, P	1
Ramée, MP	1
Bellissant, E	1
Lal, A	1
Veinot, JP	1
Leenen, FH	1
AOKI, K	1
SELLER, RH	1
SWARTZ, CD	1
RAMIREZ-MUXO, O	1
BREST, AH	1
MOYER, JH	1
EVANS, DW	1
FLEAR, CT	1
DOMENET, JG	1
BELLISARIO, G	1
CORDOVA, C	1
LOCOCO, G	1
NATOLI, A	1
SANTUCCI, A	1
SHETH, UK	1
VAIDYA, A	1
KHOKHANI, RC	1
SHAH, MJ	1
BIGLIERI, EG	1
SLATON, PE	1
ARSTILA, A	1
MAEKINEN, E	1
VANHA-PERTTULA, T	1
FISHER, DA	1
MORRIS, MD	1
BERNSTEIN, A	1
ODZE, M	1
CREWS, A	1
SIMON, F	1
FUKUCHI, S	2
HANATA, M	1
TAKAHASHI, H	1
DEMURA, H	1
GOTO, K	1
Tanabe, A	2
Naruse, M	2
Hara, Y	1
Sato, A	2
Tsuchiya, K	2
Nishikawa, T	1
Imaki, T	2
Takano, K	2
Ali, BH	1
Al-Qarawi, AA	1
Mahmoud, OM	1
Hashad, M	1
Liang, YH	1
Wang, JM	1
Zhou, Y	1
Jiang, XJ	1
Jiang, H	1
Huang, CX	1
Zeng, ZH	1
Luo, BH	1
Gao, YJ	1
Su, CJ	1
He, CC	1
Yi, JJ	1
Li, N	1
Lee, RM	1
Tamirisa, KP	1
Aaronson, KD	1
Koelling, TM	1
Cassis, LA	1
Helton, MJ	1
Howatt, DA	1
King, VL	1
Daugherty, A	1
Enomoto, S	1
Yoshiyama, M	1
Omura, T	1
Matsumoto, R	1
Kusuyama, T	1
Kim, S	1
Izumi, Y	1
Akioka, K	1
Iwao, H	1
Takeuchi, K	1
Yoshikawa, J	1
Cordaillat, M	1
Rugale, C	1
Casellas, D	1
Mimran, A	1
Jover, B	1
Gross, E	1
Rothstein, M	1
Dombek, S	1
Juknis, HI	1
Takaya, J	1
Isozaki, Y	1
Hirose, Y	1
Higashino, H	1
Noda, Y	1
Kobayashi, Y	1
Kessler-Icekson, G	1
Schlesinger, H	1
Freimann, S	1
Kessler, E	1
Trune, DR	1
Kempton, JB	1
Gross, ND	1
Buss, SJ	1
Backs, J	1
Kreusser, MM	1
Hardt, SE	1
Maser-Gluth, C	1
Katus, HA	1
Haass, M	1
Pérez-Rojas, J	1
Blanco, JA	1
Cruz, C	1
Trujillo, J	1
Vaidya, VS	1
Uribe, N	1
Bonventre, JV	1
Gamba, G	1
Bobadilla, NA	1
Glavas, MM	1
Yu, WK	1
Weinberg, J	1
Nishioka, T	1
Suzuki, M	1
Onishi, K	1
Takakura, N	1
Inada, H	1
Hiroe, M	1
Imanaka-Yoshida, K	1
Fernandes, ML	1
Ferro, EA	1
Beletti, ME	1
Resende, ES	1
Amaral, JS	1
Pinho, MJ	1
Soares-da-Silva, P	1
Mashiko, S	1
Ishihara, A	1
Iwaasa, H	1
Moriya, R	1
Kitazawa, H	1
Mitobe, Y	1
Ito, J	1
Gomori, A	1
Matsushita, H	1
Takahashi, T	1
MacNeil, DJ	1
Van der Ploeg, LH	1
Fukami, T	1
Kanatani, A	1
Grand, RJ	1
Di Sant'Agnese, PA	1
Talamo, RC	1
Pallavicini, JC	1
Johnston, LC	1
Grieble, HG	1
Edwards, KD	1
Sinnett, PF	1
Stewart, JH	1
Gill, JR	2
Bell, NH	2
Bartter, FC	4
Russo, R	1
Schena, FP	1
Colombo Pirola, L	1
Kao, LC	1
Warburton, D	1
Cheng, MH	1
Cedeño, C	1
Platzker, AC	1
Keens, TG	1
Dickey, RP	1
Taylor, SN	1
Curole, DN	1
Oates, NS	1
Perkins, CM	1
Lee, MR	2
Baylen, BG	1
Johnson, G	1
Tsang, R	1
Srivastava, L	1
Kaplan, S	1
Hoefnagels, WH	1
Drayer, JI	2
Smals, AG	1
Kloppenborg, PW	2
Fogel, MR	1
Sawhney, VK	1
Neal, EA	1
Miller, RG	1
Knauer, CM	1
Gregory, PB	1
Schalekamp, MA	1
Wenting, GJ	1
Man in 't Veld, AJ	1
Waldorff, S	1
Berning, J	1
Buch, J	1
Steiness, E	1
Jackson, PR	1
Ramsay, LE	3
Wakefield, V	1
Roos, JC	1
Boer, P	2
Peuker, KH	1
Dorhout Mees, EJ	2
Blum, I	1
Bruhis, S	1
Kaufman, H	1
Miguet, JP	1
Vuitton, D	1
Thebault-Lucas, A	1
Joanne, C	1
Dhumeaux, D	1
Silas, JH	1
Freestone, S	1
Marcondes, JA	1
Minanni, SL	1
Luthold, WW	1
Lerário, AC	1
Nery, M	1
Mendonça, BB	1
Wajchenberg, BL	1
Kirschner, MA	1
Fahlke, C	1
Hård, E	1
Eriksson, CJ	1
Engel, JA	1
Hansen, S	1
Kourounakis, PN	1
Rekka, E	1
Applefeld, JJ	1
Kasmer, RJ	1
Hak, LJ	1
Dukes, GE	1
Wermeling, DP	1
McClain, CJ	1
Bhathena, SJ	1
Canary, JJ	1
Smith, PM	1
Glen, ML	1
Gannon, CA	1
Kennedy, BW	1
Werman, MJ	1
Shephard, RJ	1
Dagnault, A	1
Deshaies, Y	1
Richard, D	1
Greene, EL	1
Kren, S	1
Hostetter, TH	1
Lijnen, P	1
Petrov, V	1
Wenzl, HH	1
Fine, KD	1
Santa Ana, CA	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications[NCT01406015]		38 participants (Actual)	Interventional	2009-02-28	Completed
HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial[NCT03476616]	Phase 4	330 participants (Anticipated)	Interventional	2018-09-01	Not yet recruiting
Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2019-01-09	Completed
Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease[NCT01721655]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2012-10-31	Recruiting
Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658]	Phase 3	90 participants (Anticipated)	Interventional	2017-08-01	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Insulin resistance was measured using the 75 G glucose tolerance test. Participants ingested 75 grams of glucose in 300-400 mL of water over 5 minutes. Blood samples were taken before ingesting glucose and then every 30 minutes for 120 minutes. HOMA-IR was calculated using the Insulin and glucose levels obtained. A negative change (decrease in insulin resistance) indicates improvement. (NCT01406015)
Timeframe: Baseline and Week 6 (Prior to ingesting glucose and every 30 minutes for 120 minutes)

Change From Baseline in Insulin Sensitivity Index (ISI)

Intervention	IR index (Mean)
	Baseline	Change from Baseline at Week 6
Placebo	3.4	0.1
Spironolactone	2.7	0.1

Insulin sensitivity was measured using the 75 gram (G) glucose tolerance test. Participants ingested 75 grams of glucose in 300-400 milliliters (mL) of water over 5 minutes. Blood samples were taken before ingesting glucose and then every 30 minutes for 120 minutes. Insulin sensitivity index was calculated by Matsuda and Defronzo's formula using the values obtained. A positive change from Baseline (increase in insulin sensitivity) indicates improvement. (NCT01406015)
Timeframe: Baseline and Week 6 (Prior to ingesting glucose and every 30 minutes for 120 minutes)

Change From Baseline in Para-aminohippurate (PAH) Clearance

Intervention	IS index (Mean)
	Baseline	Change from Baseline at Week 6
Placebo	4.6	-1.1
Spironolactone	3.7	-0.1

Renal plasma blood flow was determined by clearance of para-aminohippurate (PAH). A loading dose of PAH (8 mg/kg) was given intravenously followed by a 1 hour constant infusion of PAH at a rate of 12 mg/minute (min). Plasma samples were obtained at Baseline and at 50 and 60 minutes. PAH clearance was calculated from the plasma levels and infusion rates and reported in millimeters (mL)/minute (min). A positive change from Baseline indicates improvement. (NCT01406015)
Timeframe: Baseline and Week 6 (Prior to PAH infusion and at 50 and 60 minutes post PAH infusion)

Change From Baseline in Post-ischemic Dilatation

Intervention	mL/min (Mean)
	Baseline	Change from Baseline at Week 6
Placebo	521	-5.2
Spironolactone	488	-2.3

Ultrasonography of the brachial artery was performed to evaluate endothelial function by flow mediated dilatation (FMD) studies. A blood pressure cuff was placed on the participant's upper arm and was compressed for 5 minutes. After release of compression, brachial artery diameter and blood flow velocity were measured. FMD was expressed as the percentage change in brachial artery diameter. A positive change from Baseline indicates improvement. (NCT01406015)
Timeframe: Baseline and Week 6

Article	Year
ALDOSTERONE IN CLINICAL MEDICINE. California medicine, 1964, Volume: 101 Topics: Aldosterone; Blood Volume; Body Weight; Desoxycorticosterone; Dexamethasone; Diuretics; Drug Therapy	1964
Pathogenesis of mineralocorticoid hypertension. Clinics in endocrinology and metabolism, 1981, Volume: 10, Issue:3 Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Hyperplasia, Congenital; Adult; Aldosterone; Animals; Bloo	1981
Effect of spironolactone on premenstrual syndrome symptoms. The Journal of reproductive medicine, 1987, Volume: 32, Issue:6 Topics: Adult; Aldosterone; Body Water; Body Weight; Diuretics; Female; Humans; Premenstrual Syndrome; Renin	1987
Protection by catatoxic steroids against cyclophosphamide-induced organ lesions. Virchows Archiv. A, Pathology. Pathologische Anatomie, 1970, Volume: 351, Issue:3 Topics: Adrenal Glands; Animals; Body Weight; Bone Marrow; Cyclophosphamide; Desoxycorticosterone; Enzyme In	1970

Article	Year
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Body Mass Index; Body Weight; Brachial Artery; Doubl	2014
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Body Mass Index; Body Weight; Brachial Artery; Doubl	2014
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Body Mass Index; Body Weight; Brachial Artery; Doubl	2014
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Body Mass Index; Body Weight; Brachial Artery; Doubl	2014
Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:2 Topics: Adolescent; Adult; Amiloride; Blood Pressure; Body Weight; Cross-Over Studies; Dose-Response Relatio	2015
Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure. Arquivos brasileiros de cardiologia, 2015, Volume: 104, Issue:4 Topics: Acute Disease; Aged; Aged, 80 and over; Body Weight; Creatinine; Diuretics; Female; Heart Failure; H	2015
Effects of short-term administration of tolvaptan after open heart surgery. International journal of cardiology, 2016, Oct-01, Volume: 220 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Cardiac Surgical Procedu	2016
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:8 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Diuretics; Double-Blind Metho	2010
Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 46, Issue:1 Topics: Adult; Aldosterone; Antihypertensive Agents; Anuria; Blood Pressure; Body Weight; Cross-Over Studies	2005
[Controlled clinical study on 2 antialdosterone diuretics in the nephrotic syndrome]. La Clinica terapeutica, 1984, Apr-15, Volume: 109, Issue:1 Topics: Adolescent; Adult; Aged; Blood Pressure; Body Weight; Canrenoic Acid; Clinical Trials as Topic; Diur	1984
Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. Pediatrics, 1984, Volume: 74, Issue:1 Topics: Administration, Oral; Airway Resistance; Body Weight; Bronchopulmonary Dysplasia; Chlorothiazide; Cl	1984
Diuresis in the ascitic patient: a randomized controlled trial of three regimens. Journal of clinical gastroenterology, 1981, Volume: 3 Suppl 1 Topics: Ascites; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Furosemide; Hepat	1981
Systolic time intervals during spironolactone treatment of digitalized and non-digitalized patients with ischaemic heart disease. European journal of clinical pharmacology, 1982, Volume: 21, Issue:4 Topics: Aged; Blood Pressure; Body Weight; Coronary Disease; Depression, Chemical; Digoxin; Drug Interaction	1982
Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypokalaemia. British journal of clinical pharmacology, 1982, Volume: 14, Issue:2 Topics: Adult; Aged; Benzothiadiazines; Blood Pressure; Body Weight; Diuretics; Female; Humans; Hypokalemia;	1982
Spironolactone and enzyme induction in patients with alcoholic cirrhosis. Gastroenterology, 1980, Volume: 78, Issue:5 Pt 1 Topics: Adult; Aged; Antipyrine; Body Weight; Drug Interactions; Enzyme Induction; Female; Furosemide; Human	1980
The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women. Journal of endocrinological investigation, 1995, Volume: 18, Issue:6 Topics: Adolescent; Adult; Body Weight; Dehydroepiandrosterone; Estradiol; Female; Hirsutism; Hormone Antago	1995
A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis. Alimentary pharmacology & therapeutics, 1994, Volume: 8, Issue:4 Topics: Administration, Oral; Adult; Aged; Ascites; Body Weight; Cross-Over Studies; Diuretics; Dose-Respons	1994
Cell membrane cation transport systems during aldosterone antagonism. Journal of cardiovascular pharmacology, 1996, Volume: 27, Issue:4 Topics: Adult; Biological Transport; Blood Platelets; Blood Pressure; Body Weight; Erythrocytes; Heart Rate;	1996
Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea. Digestive diseases and sciences, 1997, Volume: 42, Issue:1 Topics: Adult; Aldosterone; Body Weight; Cathartics; Diarrhea; Electrolytes; Feces; Female; Fludrocortisone;	1997
Patterns of potassium wasting in response to stepwise combinations of diuretics in nephrotic syndrome. International journal of clinical pharmacology and therapeutics, 1999, Volume: 37, Issue:7 Topics: Aged; Amiloride; Body Weight; Chlorthalidone; Diuresis; Diuretics; Drug Therapy, Combination; Female	1999
An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide. JAMA, 1977, Mar-07, Volume: 237, Issue:10 Topics: Ascites; Body Weight; Clinical Trials as Topic; Diuretics; Furosemide; Humans; Liver Cirrhosis; Plas	1977
Metolazone and spironolactone in cirrhosis and the nephrotic syndrome. Clinical pharmacology and therapeutics, 1977, Volume: 21, Issue:2 Topics: Adult; Aged; Blood Cell Count; Blood Glucose; Blood Pressure; Body Weight; Chlorides; Clinical Trial	1977
Diuretic therapies in low renin and normal renin essential hypertension. Clinical pharmacology and therapeutics, 1977, Volume: 22, Issue:1 Topics: Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Combinations	1977
Treatment of premenstrual syndrome by spironolactone. British journal of obstetrics and gynaecology, 1979, Volume: 86, Issue:2 Topics: Aldosterone; Body Weight; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Menstruatio	1979
Effect of high dose spironolactone and chlorthalidone in essential hypertension: relation to plasma renin activity and plasma volume. Australian and New Zealand journal of medicine, 1975, Volume: 5, Issue:1 Topics: Adult; Aldosterone; Body Weight; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Pl	1975
Carbenoxolone sodium for gastric ulcer. The Medical letter on drugs and therapeutics, 1975, Aug-01, Volume: 17, Issue:16 Topics: Benzothiadiazines; Body Weight; Carbenoxolone; Clinical Trials as Topic; Diuretics; Duodenal Ulcer;	1975
Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension. The American journal of cardiology, 1975, Oct-31, Volume: 36, Issue:5 Topics: Adult; Aldosterone; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials as Topic; Creatinin	1975
Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone. Contraception, 1991, Volume: 44, Issue:2 Topics: Analysis of Variance; Androstane-3,17-diol; Blood Pressure; Body Weight; Cholesterol, HDL; Ethinyl E	1991
Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. European journal of clinical pharmacology, 1986, Volume: 30, Issue:5 Topics: Aged; Blood Pressure; Body Weight; Diuretics; Electrolytes; Female; Heart Failure; Humans; Hypertens	1986
Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia. Lancet (London, England), 1973, Dec-08, Volume: 2, Issue:7841 Topics: Adult; Aged; Amiloride; Blood Pressure; Body Weight; Diuretics; Drug Therapy, Combination; Female; H	1973
Ventilatory response to spironolactone in respiratory failure. British journal of diseases of the chest, 1972, Volume: 66, Issue:1 Topics: Airway Obstruction; Body Weight; Carbon Dioxide; Clinical Trials as Topic; Humans; Hydrogen-Ion Conc	1972
[Direct positive inotropic cardiac effect of aldactone (spironolactone, canrenoate-K)]. Deutsche medizinische Wochenschrift (1946), 1972, Oct-13, Volume: 97, Issue:41 Topics: Administration, Oral; Body Weight; Carbon Dioxide; Clinical Trials as Topic; Digitalis Glycosides; D	1972
Moderate sodium restriction and diuretics in the treatment of hypertension. American heart journal, 1973, Volume: 85, Issue:1 Topics: Adult; Body Weight; Clinical Trials as Topic; Diet, Sodium-Restricted; Female; Humans; Hydrochloroth	1973
[Treatment of essential hypertension with spironolactone with reference to the plasma renin activity]. Wiener klinische Wochenschrift, 1973, Jun-08, Volume: 85, Issue:23 Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Erectile Dysfunction; Gastrointestinal Diseas	1973
Spironolactone and frusemide in cirrhosis with ascites. The British journal of clinical practice, 1973, Volume: 27, Issue:6 Topics: Adolescent; Adult; Body Weight; Clinical Trials as Topic; Diuresis; Drug Synergism; Female; Furosemi	1973
High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism. Endokrinologie, 1970, Volume: 57, Issue:1 Topics: Adult; Aged; Body Weight; Chlorides; Clinical Trials as Topic; Clopamide; Creatinine; Diet, Sodium-R	1970
Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone. Gut, 1968, Volume: 9, Issue:1 Topics: Adult; Aged; Body Weight; Female; Glycyrrhiza; Humans; Hydrochlorothiazide; Hypertension; Male; Midd	1968

Article	Year
Effect of Metabolic Adaptation by Voluntary Running Wheel Activity and Aldosterone Inhibition on Renal Function in Female Spontaneously Hypertensive Rats. Cells, 2022, 12-07, Volume: 11, Issue:24 Topics: Aldosterone; Animals; Body Weight; Female; Hypertension; Kidney; Motor Activity; Proprotein Converta	2022
The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats. Current molecular pharmacology, 2020, Volume: 13, Issue:3 Topics: Aldosterone; Animals; Antioxidants; Biomarkers; Blood Pressure; Body Weight; Cardiovascular Diseases	2020
Low-dose spironolactone ameliorates insulin resistance and suppresses elevated plasminogen activator inhibitor-1 during gestational testosterone exposure. Archives of physiology and biochemistry, 2017, Volume: 123, Issue:5 Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Drinking; Dyslipi	2017
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World journal of gastroenterology, 2017, Aug-07, Volume: 23, Issue:29 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weig	2017
Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation. Toxicologic pathology, 2018, Volume: 46, Issue:5 Topics: Animals; Body Weight; Diet, High-Fat; Drug Therapy, Combination; Fatty Liver; Liver Neoplasms, Exper	2018
Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT. European journal of heart failure, 2019, Volume: 21, Issue:5 Topics: Aged; Aged, 80 and over; Body Weight; Cardiovascular Diseases; Cause of Death; Female; Heart Failure	2019
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. American journal of physiology. Lung cellular and molecular physiology, 2013, May-15, Volume: 304, Issue:10 Topics: Aldosterone; Animals; Arterial Pressure; Body Weight; Cardiac Output; Cell Proliferation; Fibrosis;	2013
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European heart journal, 2014, Volume: 35, Issue:14 Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolo	2014
Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus. Clinical science (London, England : 1979), 2015, Volume: 129, Issue:7 Topics: Aldosterone; Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Collagen; Diabetes Me	2015
The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats. The Journal of pharmacology and experimental therapeutics, 2015, Volume: 355, Issue:1 Topics: Ammonia; Animals; Bile Ducts; Body Weight; Hemodynamics; Hepatic Encephalopathy; Kidney; Ligation; L	2015
Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats. Endocrinology, 2016, Volume: 157, Issue:10 Topics: Adrenal Glands; Aldosterone; Animals; Blood Glucose; Body Weight; Cytochrome P-450 CYP11B2; Diabetes	2016
Colectomy induces an aldosterone-mediated increase in jejunal glucose uptake in rats. Life sciences, 2017, Apr-01, Volume: 174 Topics: Animals; Body Weight; Colectomy; Colon; Diuretics; Glucose; Jejunum; Male; Postoperative Complicatio	2017
Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2008, Volume: 9, Issue:3 Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Collagen Type I; Fibrosis; Gene Expression Regula	2008
Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. American journal of physiology. Renal physiology, 2009, Volume: 296, Issue:5 Topics: Animals; Blood Pressure; Body Weight; Chronic Disease; Creatinine; Delayed Graft Function; Disease M	2009
Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. Journal of cardiovascular pharmacology, 2009, Volume: 54, Issue:6 Topics: Animals; Blood; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Carrier Protein	2009
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure. European journal of pharmacology, 2009, Nov-25, Volume: 623, Issue:1-3 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, So	2009
Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. Neuromuscular disorders : NMD, 2010, Volume: 20, Issue:1 Topics: Administration, Oral; Animals; Body Weight; Fibrosis; Glucocorticoids; Heart; Heart Diseases; Hemody	2010
Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology, 2010, Volume: 151, Issue:5 Topics: Animals; Body Weight; Cells, Cultured; Dietary Carbohydrates; Dietary Fats; Fatty Liver; Gene Expres	2010
The glucocorticoid receptor is required for experimental adrenocorticotrophic hormone-induced hypertension in mice. Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:11 Topics: Adrenocorticotropic Hormone; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Heart Rat	2010
Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2011, Volume: 12, Issue:3 Topics: Acetophenones; Aldosterone; Animals; Blood Pressure; Blotting, Western; Body Weight; Dinoprost; Eple	2011
Improvement of cognitive impairment in female type 2 diabetes mellitus mice by spironolactone. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2012, Volume: 13, Issue:1 Topics: Animals; Blood Pressure; Body Weight; Cognition Disorders; Diabetes Mellitus, Type 2; Electrolytes;	2012
Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:5 Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Collagen; Electric Stimulation; Electrocardiograp	2011
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology, 2002, Volume: 143, Issue:12 Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Body Weight; Coronary Disease; Coronary Vessels	2002
Combined effects of enalapril and spironolactone in hamsters with dilated cardiomyopathy. Journal of cardiovascular pharmacology, 2003, Volume: 41, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Cardiomyopathy, Dilated; Cricetinae;	2003
Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. American journal of hypertension, 2003, Volume: 16, Issue:4 Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Diuretics; Dose-Response Relationship,	2003
EXPERIMENTAL STUDIES ON THE RELATIONSHIP BETWEEN ENDOCRINE ORGANS AND HYPERTENSION IN SPONTANEOUSLY HYPERTENSIVE RATS. II. EFFECTS OF VARIOUS HORMONES ON BLOOD PRESSURE. Japanese heart journal, 1963, Volume: 4 Topics: Adrenocorticotropic Hormone; Aldosterone; Animals; Arginine Vasopressin; Blood Pressure; Body Weight	1963
ALDOSTERONE ANTAGONISTS IN DIURETIC THERAPY: THEIR EFFECT ON THE REFRACTORY PHASE. Archives of internal medicine, 1964, Volume: 113 Topics: Blood Chemical Analysis; Body Weight; Edema; Heart Failure; Hematocrit; Hydrochlorothiazide; Mineral	1964
SPIRONOLACTONE AS AN ADJUVANT TO THE TREATMENT OF CONGESTIVE CARDIAC FAILURE. Postgraduate medical journal, 1964, Volume: 40 Topics: Blood; Body Weight; Chlorothiazide; Heart Failure; Humans; Potassium; Sodium; Spironolactone; Urea;	1964
[PRELIMINARY RESULTS OF THE USE OF SPIROLACTONE IN PATIENTS WITH CIRCULATORY INSUFFICIENCY]. Bollettino della Societa italiana di cardiologia, 1963, Volume: 8 Topics: Body Weight; Diuresis; Electrolytes; Heart Failure; Humans; Pericarditis; Pericarditis, Constrictive	1963
CLINICAL ASSESSMENT OF DIURETICS. Indian journal of medical sciences, 1964, Volume: 18 Topics: Acetazolamide; Body Weight; Diuretics; Drug Therapy; Edema; Heart Failure; Liver Cirrhosis; Nephrosi	1964
THE EFFECT OF DIURETICS ON THE ADRENAL CORTEX OF THE RAT. Annales medicinae experimentalis et biologiae Fenniae, 1964, Volume: 42 Topics: Acetazolamide; Adrenal Cortex; Adrenal Glands; Ascorbic Acid; Body Weight; Cholesterol; Diuretics; H	1964
IDIOPATHIC EDEMA ND HYPERALDOSTERONURIA: POSTURAL VENOUS PLASMA POOLING. Pediatrics, 1965, Volume: 35 Topics: Adolescent; Aldosterone; Angiotensins; Blood Pressure; Body Weight; Drug Therapy; Edema; Ephedrine;	1965
ETHACRYNIC ACID: A NEW POTENT DIURETIC. The American journal of the medical sciences, 1965, Volume: 249 Topics: Alkalosis; Blood Chemical Analysis; Blood Urea Nitrogen; Body Weight; Digitalis Glycosides; Diuresis	1965
THE RELATIONSHIP BETWEEN VASCULAR REACTIVITY AND EXTRACELLULAR POTASSIUM. The Tohoku journal of experimental medicine, 1965, Mar-25, Volume: 85 Topics: Angiotensins; Blood Chemical Analysis; Blood Pressure; Blood Vessels; Body Weight; Chlorothiazide; C	1965
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. Journal of hypertension, 2004, Volume: 22, Issue:5 Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B	2004
Influence of spironolactone treatment on gentamicin-induced nephrotoxicity in rats. Basic & clinical pharmacology & toxicology, 2004, Volume: 95, Issue:1 Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Body Weight; Creatinine; Drug Synergism; Genta	2004
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats. Life sciences, 2004, Aug-27, Volume: 75, Issue:15 Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Central Venous Pressure;	2004
Control of vascular changes by renin-angiotensin-aldosterone system in salt-sensitive hypertension. European journal of pharmacology, 2004, Oct-25, Volume: 503, Issue:1-3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Antihypertensive Agents; Arteri	2004
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. American heart journal, 2004, Volume: 148, Issue:6 Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Algorithms; Body Weight; Case-Control Studies; Creat	2004
Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. British journal of pharmacology, 2005, Volume: 144, Issue:3 Topics: Aldosterone; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Arteriosclerosi	2005
Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. Heart (British Cardiac Society), 2005, Volume: 91, Issue:12 Topics: Animals; Blood Pressure; Blotting, Northern; Body Weight; Coronary Vessels; Echocardiography, Dopple	2005
Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 289, Issue:4 Topics: Administration, Oral; Animals; Blood Pressure; Body Weight; Cardiomegaly; Diuretics; Drug Interactio	2005
Long-term follow-up of a girl with primary aldosteronism: effect of potassium supplement. Acta paediatrica (Oslo, Norway : 1992), 2005, Volume: 94, Issue:9 Topics: Adolescent; Blood Pressure; Body Height; Body Weight; Child; Child Development; Developmental Disabi	2005
Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone. The international journal of biochemistry & cell biology, 2006, Volume: 38, Issue:3 Topics: Aldosterone; Animals; Body Weight; Collagen Type I; Glycoproteins; Heart; In Situ Hybridization; Int	2006
Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hearing research, 2006, Volume: 212, Issue:1-2 Topics: Aldosterone; Animals; Antigen-Antibody Complex; Auditory Threshold; Autoimmune Diseases; Body Weight	2006
Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. Endocrinology, 2006, Volume: 147, Issue:5 Topics: Aldosterone; Animals; Body Weight; Echocardiography; Endothelin-1; Heart; Heart Ventricles; Hemodyna	2006
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. American journal of physiology. Renal physiology, 2007, Volume: 292, Issue:1 Topics: Animals; Apoptosis; Arterioles; Blood Pressure; Body Weight; Caspase 3; Cell Adhesion Molecules; Cyc	2007
Effects of mineralocorticoid and glucocorticoid receptor blockade on hypothalamic-pituitary-adrenal function in female rats prenatally exposed to ethanol. Alcoholism, clinical and experimental research, 2006, Volume: 30, Issue:11 Topics: Adrenocorticotropic Hormone; Animals; Body Weight; Central Nervous System Depressants; Ethanol; Feed	2006
Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:5 Topics: Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blood Pressure; Body Weight; Cytokines;	2007
Spironolactone effects on myocardium changes induced by thyroid hormone in rats. Arquivos brasileiros de cardiologia, 2007, Volume: 89, Issue:6 Topics: Analysis of Variance; Animals; Body Weight; Heart; Heart Rate; Hypertrophy, Left Ventricular; Male;	2007
Genomic regulation of intestinal amino acid transporters by aldosterone. Molecular and cellular biochemistry, 2008, Volume: 313, Issue:1-2 Topics: Aldosterone; Amino Acid Transport Systems; Animals; Body Weight; Epithelial Cells; Gene Expression R	2008
Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:7 Topics: Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Caloric R	2008
The effects of exogenous aldosterone on sweat electrolytes. I. Normal subjects. The Journal of pediatrics, 1967, Volume: 70, Issue:3 Topics: Adolescent; Adult; Aldosterone; Body Weight; Child; Female; Humans; Iontophoresis; Kidney; Male; Pil	1967
Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist. Archives of internal medicine, 1967, Volume: 119, Issue:3 Topics: Adult; Bendroflumethiazide; Blood Pressure; Body Weight; Chlorthalidone; Female; Humans; Hyperaldost	1967
Ethacrynic acid: assessment of saluretic and diuretic potency in patients with severe chronic renal failure. The Medical journal of Australia, 1967, Feb-25, Volume: 1, Issue:8 Topics: Adult; Aged; Bendroflumethiazide; Blood Urea Nitrogen; Body Weight; Chlorides; Creatine; Diuretics;	1967
Impaired conservation of sodium and potassium in renal tubular acidosis and its correction by buffer anions. Clinical science, 1967, Volume: 33, Issue:3 Topics: Acid-Base Equilibrium; Acidosis, Renal Tubular; Adolescent; Adult; Aldosterone; Bicarbonates; Body W	1967
Serum estradiol and danazol. I. Endometriosis response, side effects, administration interval, concurrent spironolactone and dexamethasone. Fertility and sterility, 1984, Volume: 42, Issue:5 Topics: Adult; Age Factors; Body Weight; Danazol; Dexamethasone; Drug Administration Schedule; Drug Therapy,	1984
The effect of mineralocorticoid administration on urine free dopamine in man. Clinical science (London, England : 1979), 1980, Volume: 58, Issue:1 Topics: Adult; Body Weight; Dopamine; Fludrocortisone; Humans; Hyperaldosteronism; Kidney; Male; Potassium;	1980
The occurrence of hyperaldosteronism in infants with congestive heart failure. The American journal of cardiology, 1980, Volume: 45, Issue:2 Topics: Aldosterone; Body Weight; Epidemiologic Methods; Furosemide; Heart Failure; Humans; Hyperaldosteroni	1980
Spironolactone and amiloride in hypertensive patients with and without aldosterone excess. Clinical pharmacology and therapeutics, 1980, Volume: 27, Issue:3 Topics: Adult; Amiloride; Blood Pressure; Body Weight; Female; Humans; Hyperaldosteronism; Hypertension; Mal	1980
Changes in intrarenal uric acid handling during chronic spironolactone treatment in patients with essential hypertension. Nephron, 1982, Volume: 32, Issue:3 Topics: Body Weight; Chlorthalidone; Female; Humans; Hypertension; Kidney; Male; Spironolactone; Uric Acid	1982
Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. Fertility and sterility, 1981, Volume: 35, Issue:6 Topics: Adult; Blood Pressure; Body Weight; Bromocriptine; Drug Therapy, Combination; Female; Glucose Tolera	1981
Diuretic treatment of resistant hypertension. British medical journal, 1980, Oct-25, Volume: 281, Issue:6248 Topics: Adult; Aged; Bendroflumethiazide; Body Weight; Cyclopenthiazide; Drug Resistance; Female; Furosemide	1980
Consequence of long-term exposure to corticosterone or dexamethasone on ethanol consumption in the adrenalectomized rat, and the effect of type I and type II corticosteroid receptor antagonists. Psychopharmacology, 1995, Volume: 117, Issue:2 Topics: Adrenalectomy; Alcohol Drinking; Animals; Body Weight; Corticosterone; Dexamethasone; Drinking; Drug	1995
Effect of spironolactone on dimethyl mercury toxicity. A possible molecular mechanism. Arzneimittel-Forschung, 1994, Volume: 44, Issue:10 Topics: Alanine Transaminase; Animals; Bilirubin; Blood Urea Nitrogen; Body Weight; Ethylmorphine-N-Demethyl	1994
Opioid peptides, adrenocorticotrophic hormone, and idiopathic (orthostatic) edema. The American journal of the medical sciences, 1994, Volume: 308, Issue:2 Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; beta-Endorphin; Blood Urea Nitrogen; Body Weight; D	1994
Electrolyte manipulation in female body-builders. British journal of sports medicine, 1994, Volume: 28, Issue:1 Topics: Body Water; Body Weight; Dietary Carbohydrates; Feeding Behavior; Female; Humans; Potassium; Sodium,	1994
Involvement of type I corticosteroid receptor in the effects of ovariectomy on energy balance. The American journal of physiology, 1996, Volume: 270, Issue:1 Pt 2 Topics: Animals; Body Weight; Energy Metabolism; Female; Lipid Metabolism; Mifepristone; Mineralocorticoid R	1996
Role of aldosterone in the remnant kidney model in the rat. The Journal of clinical investigation, 1996, Aug-15, Volume: 98, Issue:4 Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biph	1996
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension (Dallas, Tex. : 1979), 1998, Volume: 31, Issue:1 Pt 2 Topics: Aging; Animals; Body Weight; Brain; Cerebrovascular Disorders; Delayed-Action Preparations; Diuresis	1998
A reliable, practical, and economical protocol for inducing diarrhea and severe dehydration in the neonatal calf. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 1998, Volume: 62, Issue:3 Topics: Animals; Animals, Newborn; Blood Glucose; Blood Proteins; Body Temperature; Body Weight; Cattle; Col	1998
Differential induction of glutathione S-transferase subunits by spironolactone in rat liver, jejunum and colon. Life sciences, 1998, Volume: 63, Issue:26 Topics: Animals; Body Weight; Colon; Dose-Response Relationship, Drug; Enzyme Induction; Glutathione Transfe	1998
Population analysis for the optimization of digoxin treatment in Japanese paediatric patients. Journal of clinical pharmacy and therapeutics, 1999, Volume: 24, Issue:3 Topics: Age Factors; Body Weight; Cardiotonic Agents; Child; Child, Preschool; Digoxin; Drug Interactions; F	1999
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension (Dallas, Tex. : 1979), 2001, Volume: 37, Issue:2 Pt 2 Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Ca	2001
Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension (Dallas, Tex. : 1979), 2001, Volume: 37, Issue:2 Pt 2 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; Aorta; Blood Pressure; Body Weight; Endothelin	2001
Heart biometry and allometry in rats submitted to nitric oxide synthesis blockade and treatment with antihypertensive drugs. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft, 2001, Volume: 183, Issue:2 Topics: Animals; Antihypertensive Agents; Body Weight; Enalapril; Heart; Heart Ventricles; Male; NG-Nitroarg	2001
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. British journal of pharmacology, 2001, Volume: 133, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Blood Glucose; Body Weight; Calci	2001
Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2001, Volume: 281, Issue:3 Topics: Aldosterone; Animals; Aorta; Basal Ganglia; Blood Pressure; Body Weight; Cerebral Cortex; Cerebral I	2001
Role of renin-angiotensin-aldosterone system in salt-sensitive hypertension induced by sensory denervation. American journal of physiology. Heart and circulatory physiology, 2001, Volume: 281, Issue:5 Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Capsaicin; Denervation; Female; Hypertension; Min	2001
Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:1 Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals;	2002
Diuretic-induced oedema. Lancet (London, England), 1975, Mar-01, Volume: 1, Issue:7905 Topics: Adult; Aldosterone; Blood Volume; Body Weight; Chlorthalidone; Diuretics; Edema; Female; Furosemide;	1975
[Long term therapy over nine years with Spironolacton in hydropic cardiac insufficiency]. Medizinische Klinik, 1976, Sep-17, Volume: 71, Issue:38 Topics: Aged; Blood Pressure; Body Weight; Cardiac Glycosides; Cardiomegaly; Diuretics; Drug Therapy, Combin	1976
Idiopathic edema as a cause of nonarticular rheumatism. Arthritis and rheumatism, 1979, Volume: 22, Issue:4 Topics: Adult; Body Weight; Capillary Permeability; Chlorthalidone; Dextroamphetamine; Edema; Female; Humans	1979
Treatment of Bartter's syndrome in early childhood with prostaglandin synthetase inhibitors. Archives of disease in childhood, 1978, Volume: 53, Issue:1 Topics: Bartter Syndrome; Body Height; Body Weight; Child, Preschool; Cyclooxygenase Inhibitors; Humans; Hyp	1978
Mineralocorticoid-induced blood pressure, electrolyte, and hormone changes, and reversal with spironolactone, in healthy men. Metabolism: clinical and experimental, 1979, Volume: 28, Issue:5 Topics: Adult; Blood Pressure; Body Weight; Fludrocortisone; Heart Rate; Humans; Kidney; Male; Potassium; So	1979
Opposing effects of deoxycorticosterone and spironolactone on isoprenaline-induced myocardial infarction. Cardiovascular research, 1979, Volume: 13, Issue:2 Topics: Animals; Body Weight; Corticosterone; Desoxycorticosterone; Isoproterenol; Lipids; Male; Myocardial	1979
Haemodynamic effects of treatment and withdrawal of spironolactone in essential hypertension. Scandinavian journal of clinical and laboratory investigation, 1979, Volume: 39, Issue:2 Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Urea Nitrogen; Body Weight; Cardiac Output; Creatini	1979
Idiopathic edema: pathogenesis, clinical features, and treatment. Metabolism: clinical and experimental, 1978, Volume: 27, Issue:3 Topics: Adrenalectomy; Body Weight; Capillaries; Capillary Permeability; Edema; Female; Humans; Hyperaldoste	1978
Congenital pseudohypoaldosteronism: case report and review. Effect of indomethacin during sodium chloride depletion. Helvetica paediatrica acta, 1978, Volume: 33, Issue:2 Topics: Adrenal Insufficiency; Aldosterone; Body Weight; Chlorides; Desoxycorticosterone; Diagnosis, Differe	1978
Role of aldosterone in the antihypertensive effect of spironolactone in essential hypertension. Clinical pharmacology and therapeutics, 1978, Volume: 24, Issue:6 Topics: Adult; Aldosterone; Blood Pressure; Body Weight; Electrolytes; Female; Humans; Hypertension; Kidney;	1978
Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney international, 1978, Volume: 14, Issue:3 Topics: Adult; Aldosterone; Body Weight; Creatinine; Diet; Female; Humans; Kidney Failure, Chronic; Male; Mi	1978
[Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)]. MMW, Munchener medizinische Wochenschrift, 1975, Volume: 117, Issue:37 Topics: Administration, Oral; Aged; Blood Pressure; Body Weight; Canrenoic Acid; Female; Heart Failure; Huma	1975
Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney international, 1976, Volume: 9, Issue:3 Topics: Adult; Bartter Syndrome; Body Weight; Dose-Response Relationship, Drug; Humans; Hyperaldosteronism;	1976
Effect of phenobarbital, spironolactone and pregnenolone-16 alpha-carbonitrile on bile formation in the rat. Naunyn-Schmiedeberg's archives of pharmacology, 1975, Volume: 287, Issue:1 Topics: Animals; Bile; Bile Acids and Salts; Body Weight; Cholesterol; Liver; Male; Organ Size; Phenobarbita	1975
[Renal and extrarenal mechanisms of potassium homeostasis following a potassium load]. Fiziologicheskii zhurnal SSSR imeni I. M. Sechenova, 1975, Volume: 61, Issue:3 Topics: Adrenal Cortex Hormones; Adrenal Glands; Adrenalectomy; Animals; Body Weight; Female; Femoral Vein;	1975
[Use of aldactone-saltucine in patients with heart failure]. Kardiologiia, 1975, Volume: 15, Issue:5 Topics: Adult; Aged; Aldosterone; Body Weight; Butanes; Chlorides; Diuretics; Drug Combinations; Drug Evalua	1975
[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]. Deutsche medizinische Wochenschrift (1946), 1975, Mar-21, Volume: 100, Issue:12 Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Body Weight; Butanes; Female; Furosemide; Huma	1975
Determinants of deranged sodium and water homeostasis in decompensated cirrhosis. The Journal of laboratory and clinical medicine, 1976, Volume: 87, Issue:5 Topics: Adult; Aldosterone; Body Weight; Creatinine; Desoxycorticosterone; Diet; Homeostasis; Humans; Immers	1976
Effect of chronic treatment with clonidine and spironolactone on cold-induced elevation of blood pressure. Pharmacology, 1991, Volume: 43, Issue:4 Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Body Weight; Clonidine; Cold Temperature; Drin	1991
Effect of a new mineralocorticoid antagonist mespirenone on aldosterone-induced hypertension. The American journal of physiology, 1991, Volume: 260, Issue:2 Pt 1 Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Hypertension; Male; Mineralocorticoid Receptor An	1991
Response of exocrine pancreas to corticosterone and aldosterone after adrenalectomy. Journal of steroid biochemistry, 1989, Volume: 33, Issue:6 Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Amylases; Animals; Body Weight; Corticosterone; Female;	1989
Additive effect of combined spironolactone and phenobarbital treatment on hepatic bilirubin UDP-glucuronyltransferase. Biochemical pharmacology, 1989, Mar-01, Volume: 38, Issue:5 Topics: Animals; Body Weight; Drug Synergism; Enzyme Induction; Glucuronosyltransferase; Male; Microsomes, L	1989
Comparative study of acetazolamide and spironolactone on body fluid compartments on induction to high altitude. International journal of biometeorology, 1986, Volume: 30, Issue:1 Topics: Acetazolamide; Adult; Altitude; Blood Viscosity; Body Fluid Compartments; Body Fluids; Body Weight;	1986
Biochemical and morphometric analysis of the effect of spironolactone on the livers from immature and adult rats. Archives internationales de pharmacodynamie et de therapie, 1987, Volume: 290, Issue:2 Topics: Aging; Animals; Body Weight; Cell Nucleus; Cytoplasm; Liver; Macromolecular Substances; Male; Organ	1987
Effect of spironolactone on renal prostaglandin excretion in patients with liver cirrhosis and ascites. Journal of hepatology, 1986, Volume: 3, Issue:2 Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Ascites; Body Weight; Dinoprostone; Fe	1986
Adaptation to chronic potassium loading in normal man. Mineral and electrolyte metabolism, 1986, Volume: 12, Issue:3 Topics: Acetazolamide; Adaptation, Biological; Administration, Oral; Adult; Aldosterone; Body Weight; Canren	1986
Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology, 1986, Volume: 90, Issue:6 Topics: Amiloride; Ascites; Body Weight; Chronic Disease; Diuresis; Edema; Electrolytes; Furosemide; Humans;	1986
Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. Nephron, 1986, Volume: 44, Issue:4 Topics: Adult; Ascites; Body Weight; Creatinine; Drug Therapy, Combination; Edema; Furosemide; Humans; Hypon	1986
In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clinical endocrinology, 1985, Volume: 23, Issue:4 Topics: Animals; Body Weight; Canrenoic Acid; Cytosol; Kidney; Male; Mice; Orchiectomy; Organ Size; Pregnadi	1985
Total-body potassium in hypertension patients during prolonged diuretic therapy. Lancet (London, England), 1972, Jul-01, Volume: 2, Issue:7766 Topics: Adult; Aged; Body Weight; Diuretics; Female; Humans; Hypertension; Long-Term Care; Male; Middle Aged	1972
[Pilot study on the efficacy of high doses of aldosterone and spirolactone derivatives in the treatment of multiple sclerosis]. Zeitschrift fur Neurologie, 1972, Volume: 202, Issue:3 Topics: Adult; Aldosterone; Blood Pressure Determination; Body Weight; Chronic Disease; Electrocardiography;	1972
Total exchangeable potassium, sodium and chloride in patients with severe valvular heart disease during preparation for cardiac surgery. Scandinavian journal of thoracic and cardiovascular surgery, 1973, Volume: 7, Issue:1 Topics: Adult; Aortic Valve Insufficiency; Atrial Fibrillation; Bicarbonates; Blood Proteins; Body Compositi	1973
Changes in blood-volume produced by treatment in the nephrotic syndrome. Lancet (London, England), 1967, Oct-14, Volume: 2, Issue:7520 Topics: Adolescent; Adult; Aged; Blood Volume; Blood Volume Determination; Body Weight; Child; Chlorothiazid	1967
Sodium retention after adrenal enucleation: drug and salt appetite studies. Endocrinology, 1968, Volume: 83, Issue:5 Topics: Adrenal Glands; Adrenal Medulla; Adrenalectomy; Aminoglutethimide; Animals; Appetite; Body Weight; D	1968
Hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension (Bartter's syndrome). The American journal of medicine, 1968, Volume: 44, Issue:5 Topics: 17-Ketosteroids; Adrenocorticotropic Hormone; Aldosterone; Ammonium Chloride; Angiotensin II; Bicarb	1968
Neurodegenerative disorders and hyperaldosteronism. The Journal of pediatrics, 1971, Volume: 79, Issue:4 Topics: Adolescent; Aldosterone; Angiotensin II; Birth Weight; Blood Pressure; Body Weight; Bundle-Branch Bl	1971
Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. British medical journal, 1972, Jun-24, Volume: 2, Issue:5816 Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adult; Aged; Aldosterone; Angiotensin II; Blood Pr	1972
Angiotensin-salt hypertension. Clinical science and molecular medicine. Supplement, 1973, Volume: 45 Suppl 1 Topics: Angiotensin II; Animals; Body Fluids; Body Weight; Diet, Sodium-Restricted; Hypertension; Kidney Med	1973
Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients. Circulation, 1972, Volume: 45, Issue:3 Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Digital	1972
Plasma aldosterone in essential hypertension with low renin activity. Japanese circulation journal, 1974, Volume: 38, Issue:12 Topics: Aldosterone; Body Weight; Corticosterone; Cushing Syndrome; Furosemide; Humans; Hydrochlorothiazide;	1974
[Treatment of resistant ascites in cirrhotic patients]. L'union medicale du Canada, 1974, Volume: 103, Issue:12 Topics: Aged; Ascites; Body Weight; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Potassium; Sodium; S	1974
Spironolactone in diuretic regimens with meralluride or thiazides for pseudointractable ascites of cirrhosis. The Journal of clinical pharmacology and new drugs, 1972, Volume: 12, Issue:1 Topics: Administration, Oral; Adult; Aged; Body Weight; Diuresis; Diuretics; Drug Combinations; Drug Synergi	1972
[Bile secretion and I 131 BSP excretion of the gallbladder as influenced by spirolactone in animal experiment]. Zeitschrift fur Gastroenterologie, 1972, Volume: 10, Issue:7 Topics: Animals; Bile; Body Weight; Gallbladder; Iodine Radioisotopes; Liver; Liver Function Tests; Male; Or	1972
[Treatment of arterial hypertension with new drugs. 1. Severe arterial hypertension]. Acquisitions medicales recentes, 1972 Topics: Antihypertensive Agents; Body Weight; Clonidine; Diuresis; Furosemide; Hemodynamics; Humans; Hyperte	1972
The diagnostic and therapeutic value of spironolactone in patients with systemic hypertension. Nephron, 1973, Volume: 9, Issue:3 Topics: Acid-Base Equilibrium; Adenoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aldosterone; Blood Press	1973
Spironolactone as a nonspecific treatment for primary aldosteronism. Circulation, 1973, Volume: 48, Issue:3 Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Urea Nitrogen; Body Weight; Carbon Dioxide; Creatini	1973
Effect of various steroids on the hepatic glucuronidation and biliary excretion of bilirubin. Canadian journal of physiology and pharmacology, 1973, Volume: 51, Issue:5 Topics: Animals; Bile; Bile Pigments; Bilirubin; Body Weight; Female; Glucuronates; Hexosyltransferases; Hyd	1973
Interactions of aspirin, indomethacin and other drugs in adjuvant-induced arthritis in the rat. The Journal of pharmacology and experimental therapeutics, 1973, Volume: 187, Issue:2 Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Arthritis; Aspirin; Body Weight; Chlorpromazine; C	1973
Antiandrogenic effect of spironolactone in rats. The Journal of urology, 1974, Volume: 111, Issue:1 Topics: Androgen Antagonists; Animals; Atrophy; Body Weight; Cytoplasm; Epithelial Cells; Injections, Subcut	1974
Salt-poor human albumin in management of nephrotic syndrome. British medical journal, 1974, Mar-16, Volume: 1, Issue:5906 Topics: Adolescent; Adult; Aged; Albumins; Body Weight; Creatinine; Diet Therapy; Dietary Proteins; Edema; F	1974
[Malignant arterial hypertension. Intensive treatment by acute sodium depletion and antihypertensive agents]. La Nouvelle presse medicale, 1972, Jan-29, Volume: 1, Issue:5 Topics: Adult; Antihypertensive Agents; Body Weight; Creatinine; Diet, Sodium-Restricted; Diuretics; Female;	1972
Idiopathic edema. II. Pathogenesis of edema in patients with hypoalbuminemia. The American journal of medicine, 1972, Volume: 52, Issue:4 Topics: Adrenal Glands; Adult; Aldosterone; Blood Protein Disorders; Body Weight; Creatinine; Edema; Female;	1972
Effect of spironolactone on urinary calcium excretion. Israel journal of medical sciences, 1972, Volume: 8, Issue:4 Topics: Adult; Blood Chemical Analysis; Blood Pressure Determination; Body Weight; Calcium; Creatinine; Diur	1972
[Water-sodium depletion and clonidine in severe arterial hypertension]. Maroc medical, 1972, Volume: 52, Issue:556 Topics: Adult; Antihypertensive Agents; Body Weight; Clonidine; Creatinine; Drug Synergism; Electrocardiogra	1972
[Electrocardiographic observations in secondary aldosteronism]. Medizinische Klinik, 1972, Jan-28, Volume: 67, Issue:4 Topics: Aged; Aldosterone; Body Weight; Digitalis Glycosides; Diuresis; Electrocardiography; Female; Heart F	1972
Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity. Archives of internal medicine, 1972, Volume: 130, Issue:6 Topics: Adult; Blood Pressure; Body Weight; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle	1972
[Joint study on the effectiveness of diuretic measures in hydropic diseases. IV. Statistical analysis of the relationship of the data collected]. Klinische Wochenschrift, 1971, Sep-15, Volume: 49, Issue:18 Topics: Ascites; Biometry; Body Weight; Diet Therapy; Diuresis; Diuretics; Edema; Factor Analysis, Statistic	1971
Some factors affecting onset of adrenal-regeneration hypertension (ARH) and the antihypertensive influence of spironolactone on established ARH. Texas reports on biology and medicine, 1971, Volume: 29, Issue:2 Topics: Adrenalectomy; Animals; Blood Pressure; Body Weight; Drinking Behavior; Feeding Behavior; Female; Hy	1971
Hypertension and low plasma renin activity: presumptive evidence for mineralocorticoid excess. Annals of internal medicine, 1971, Volume: 75, Issue:6 Topics: Adrenal Glands; Aldosterone; Blood Pressure; Body Weight; Carbon Dioxide; Chlorides; Female; Humans;	1971
Treatment of cor pulmonale decompensatum with diuretics. Therapia Hungarica (English edition), 1971, Volume: 19, Issue:4 Topics: Acidosis, Respiratory; Blood Gas Analysis; Body Weight; Diuresis; Diuretics; Drug Resistance; Drug S	1971
Anti-androgenic activity of spironolactone. Steroids, 1969, Volume: 14, Issue:4 Topics: Androgen Antagonists; Animals; Body Weight; Humans; Male; Organ Size; Prostate; Rats; Seminal Vesicl	1969
Prevention of digitoxin poisoning by various steroids. Journal of pharmaceutical sciences, 1969, Volume: 58, Issue:9 Topics: Anabolic Agents; Androstanes; Animals; Body Weight; Desoxycorticosterone; Digitoxin; Diuretics; Estr	1969
Severe hypernatremia complicating heart valve surgery. A preliminary report. Scandinavian journal of thoracic and cardiovascular surgery, 1969, Volume: 3, Issue:1 Topics: Aortic Valve; Aortic Valve Stenosis; Body Weight; Chlorides; Heart Failure; Heart Valve Prosthesis;	1969
Hypertension and hyperaldosteronism with low plasma renin concentration: analysis of a series of eighty-two patients. Proceedings of the Royal Society of Medicine, 1969, Dec-12, Volume: 62, Issue:12 Topics: Adrenal Glands; Aldosterone; Body Weight; Humans; Hyperaldosteronism; Hypertension; Plasma Volume; P	1969
Stenosis of the inferior vena cava with secondary hyperaldosteronism. Acta paediatrica Academiae Scientiarum Hungaricae, 1969, Volume: 10, Issue:2 Topics: Angiography; Body Weight; Constriction; Diuresis; Diuretics; Edema; Humans; Hyperaldosteronism; Infa	1969
[Induced aldosteronism in hydropic heart insufficiency]. Klinische Wochenschrift, 1969, Jan-01, Volume: 47, Issue:1 Topics: Acid-Base Equilibrium; Adult; Aged; Aldosterone; Body Weight; Carbon Isotopes; Cardiac Glycosides; E	1969
[Effect of diuretic measures in hydropic conditions. I. Planning, results in heart insufficiency]. Klinische Wochenschrift, 1969, Nov-01, Volume: 47, Issue:21 Topics: Adult; Aged; Body Weight; Diet, Sodium-Restricted; Diuresis; Diuretics; Documentation; Edema; Female	1969
[Effect of diuretic measures in hydropic conditions. II. Results in liver cirrhosis]. Klinische Wochenschrift, 1969, Nov-01, Volume: 47, Issue:21 Topics: Adult; Aged; Body Weight; Diet, Sodium-Restricted; Diuresis; Diuretics; Documentation; Edema; Female	1969
[Effect of diuretic measures in hydropic condition. 3. Results in nephrotic syndrome, comparison with other disease groups]. Klinische Wochenschrift, 1969, Nov-01, Volume: 47, Issue:21 Topics: Adult; Body Weight; Diet, Sodium-Restricted; Diuresis; Diuretics; Edema; Female; Glomerulonephritis;	1969
[Effect of hormones on physical and chemical properties of connective- and supporting tissue. 1]. Arzneimittel-Forschung, 1969, Volume: 19, Issue:9 Topics: Acetates; Adrenalectomy; Age Factors; Aldosterone; Animals; Body Weight; Connective Tissue; Corticos	1969
Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870). Metabolism: clinical and experimental, 1970, Volume: 19, Issue:1 Topics: Adult; Aged; Bicarbonates; Blood Pressure; Body Weight; Chemical Phenomena; Chemistry; Chlorides; Cr	1970
The syndrome of primary aldosteronism. The American journal of medicine, 1970, Volume: 48, Issue:3 Topics: 17-Hydroxycorticosteroids; Adenoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aldosterone; Blood U	1970
Evidence for spironolactone as a possible inducer of liver microsomal enzymes in mice. Biochemical pharmacology, 1970, Volume: 19, Issue:8 Topics: Aniline Compounds; Animals; Body Weight; Enzyme Induction; Hexobarbital; Liver; Male; Metabolism; Mi	1970
[Acid-base equilibrium and blood gas analysis in clinical cardiology]. Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete, 1970, Volume: 51, Issue:7 Topics: Acetazolamide; Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Body Weight; Diagnosis, Diff	1970
Pretibial edema and sodium retention during lithium carbonate treatment. JAMA, 1970, Dec-07, Volume: 214, Issue:10 Topics: Adult; Age Factors; Aldosterone; Bipolar Disorder; Body Weight; Carbonates; Diet; Edema; Female; Hum	1970
Effects of vasopressin and spironolactone on excretion of water and solutes by the pregnant rat. The American journal of physiology, 1968, Volume: 214, Issue:6 Topics: Animals; Body Weight; Extracellular Space; Female; Inulin; Potassium; Pregnancy; Pregnancy, Animal;	1968
[Clinical experience with a new spironolactone-thiabuzide combination]. Medizinische Klinik, 1968, Jun-07, Volume: 63, Issue:23 Topics: Aged; Body Weight; Digoxin; Diuretics; Drug Synergism; Edema; Female; Furosemide; Glycosuria; Humans	1968
Aldosteronism in hypertension. The spironolactone response test. Annals of internal medicine, 1968, Volume: 69, Issue:4 Topics: Adrenalectomy; Aldosterone; Blood Pressure; Body Weight; Diagnosis, Differential; Electrolytes; Huma	1968
Metabolic studies on hypertensive patients with suppressed plasma renin activity not due to hyperaldosternosm. Circulation, 1968, Volume: 38, Issue:5 Topics: Adult; Aldosterone; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Blood Volume; Body Weight; E	1968
The nephrotic syndrome in an elderly woman. An unusual association with an unusual response to therapy. Geriatrics, 1969, Volume: 24, Issue:6 Topics: Aged; Biopsy; Body Weight; Chronic Disease; Diagnosis, Differential; Edema; Female; Humans; Hydrochl	1969
Newer diuretics in the treatment of cardiac or hepatic disease in elderly patients. Journal of the American Geriatrics Society, 1966, Volume: 14, Issue:12 Topics: Ascites; Benzothiadiazines; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cardiovascular Diseases	1966

spironolactone and Body Weight